Clinical trials: Nutritional Evaluation
Overweight, Obesity
Benefit and Tolerability of IQP-LU-104 in Weight Loss
This study is to evaluate the benefit and tolerability of two dosages of IQP-LU-104 (5120mg and 2560mg daily) in reducing body weight in overweight and moderately obese subjects
- Trial name
- NCT03888911
- Testing
- High dose IQP-LU-104 (5120mg), Low dose IQP-LU-104 (2560mg)
- Where
- Germany
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Gaucher Disease
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
The primary objective of this study was to evaluate the efficacy and safety of once daily (QD) versus twice daily (BID) dosing of eliglustat tartrate (Genz-112638) in participants with Gaucher disease type 1 who had demonstrated…
- Trial name
- NCT01074944
- Testing
- Eliglustat tartrate
- Where
- 46 sites in United States, Australia and 15 more
- Volunteers
- 170 people
- Sponsor
- Genzyme, a Sanofi Company
Fabry Disease
A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease
The primary purpose of this study was to assess the safety and tolerability of lucerastat in adults with Fabry Disease receiving Enzyme Replacement Therapy (ERT).
- Trial name
- NCT02930655
- Testing
- Lucerastat, Enzyme replacement therapy (ERT)
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Type 2 Diabetes
A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes
The purpose of this study is to determine whether SLx-4090 in combination with metformin therapy will reduce HbA1c in patients with Type 2 Diabetes more effectively than metformin therapy alone.
- Trial name
- NCT00871936
- Testing
- SLx-4090, Metformin
- Where
- 12 sites in United States
- Volunteers
- 82 people
- Sponsor
- Response Pharmaceuticals
Overweight and Obesity
Evaluation of Fiit-ns® in Health-related Quality of Life Improvement in Overweight and Obese Subjects
The purpose of this study is to evaluate the effects of a 16-week supplementation with a polyphenol-rich extract, Fiit-ns®, on improvement of health-related quality of life (HR-QOL) of overweight and obese volunteers, as compared…
- Trial name
- NCT03423719
- Testing
- Fiit-ns®
- Where
- Spain
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Fytexia
ASCVD, Risk Factor, Cardiovascular
Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol
This is a Phase III, placebo-controlled, double-blind, randomized study in participants with ASCVD or ASCVD-Risk equivalents and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies to evaluate the efficacy…
- Conditions
- ASCVD, Risk Factor, Cardiovascular, Elevated Cholesterol
- Trial name
- ORION-11 (NCT03400800)
- Testing
- Inclisiran Sodium
- Where
- 70 sites in Czechia, Germany and 5 more
- Volunteers
- 1,617 people
- Sponsor
- The Medicines Company
Obesity, Non-Alcoholic SteatoHepatitis (NASH)
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)
This study is open to adults who are at least 18 years old and have presumed or confirmed NASH together with overweight or obesity and a body mass index (BMI) of 30 kg/m² or more, or a BMI of 27 kg/m² and at least one…
- Trial name
- NCT06309992
- Testing
- Survodutide
- Where
- 37 sites in United States, Spain
- Volunteers
- 218 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Valsartan/Hydrochlorothiazide Combination vs Amlodipine in Patients With Hypertension, Diabetes, and Albuminuria.
The purpose of this study is assess if treatment with valsartan and a diuretic, hydrochlorothiazide, has beneficial effects in people with high blood pressure, diabetes, and albuminuria (protein in the urine) compared with…
- Trial name
- NCT00171561
- Testing
- valsartan/hydrochlorothiazide
- Where
- Switzerland
- Volunteers
- 144 people
- Sponsor
- Novartis
Gastroparesis
Different Doses of Naronapride vs. Placebo in Gastroparesis
This is a double-blind, randomized, multicenter, placebo-controlled, comparative phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to…
- Trial name
- MOVE-IT (NCT05621811)
- Testing
- Naronapride
- Where
- 24 sites in United States, Belgium
- Volunteers
- 328 people
- Sponsor
- Dr. Falk Pharma GmbH
Crigler-Najjar Syndrome
Gene Transfer Clinical Study in Crigler-Najjar Syndrome
This is a Phase 1/2, multinational, open-label, ascending-dose, delayed-treatment concurrent control clinical study to evaluate the safety and preliminary efficacy of AT342 in subjects with Crigler-Najjar aged ≥1 year.
- Trial name
- VALENS (NCT03223194)
- Testing
- AT342
- Where
- 4 sites in United States, Israel and 1 more
- Volunteers
- 1 people
- Sponsor
- Audentes Therapeutics
Insulin Hypoglycemia, Type 1 Diabetes Mellitus
G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes
This is a non-inferiority, multi-center, randomized, controlled, single-blind, two-way crossover efficacy and safety study in subjects with Type 1 diabetes mellitus.
- Conditions
- Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
- Trial name
- NCT03439072
- Testing
- G-Pen, Lilly Glucagon
- Where
- 6 sites in United States, Canada
- Volunteers
- 81 people
- Sponsor
- Xeris Pharmaceuticals
Hypercholesterolemia
Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia
The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), to lower cholesterol in subjects with homozygous familial hypercholesterolemia undergoing lipid-lowering treatment.
- Trial name
- NCT00263081
- Testing
- Lapaquistat acetate and current lipid-lowering treatment, Current lipid-lowering treatment
- Where
- 10 sites in United States, Canada and 4 more
- Volunteers
- 44 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
Lantus Effect on Myocardial Glucose Metabolism in T2
The primary objective of the present study is to assess changes of myocardial glucose uptake (MGU) during clamp studies using positron emission tomography (PET) scanning in patients with type 2 diabetes and idiopathic left…
- Trial name
- NCT00335465
- Testing
- Insulin glargine
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Sanofi
Diabetes Mellitus
Long-term Study of SYR-472
To evaluate the safety and efficacy of long-term treatment with SYR-472 in diabetic patients.
- Trial name
- NCT01431807
- Testing
- SYR-472
- Where
- 41 sites in Japan
- Volunteers
- 680 people
- Sponsor
- Takeda
Hypercholesterolemia
STELLAR-Rosuvastatin vs. Atorvastatin, Pravastatin, Simvastatin Across Dose Ranges
To compare the efficacy of various doses of rosuvastatin with atorvastatin, pravastatin \& simvastatin in reducing levels of low density lipoprotein cholesterol in subjects with hypercholesterolaemia.
- Trial name
- STELLAR (NCT00654537)
- Testing
- Rosuvastatin, Atorvastatin, Pravastatin
- Volunteers
- 5,625 people
- Sponsor
- AstraZeneca
Hypertension, Hyperlipidemia
CKD-346 DDI Study(Telmisartan/S-Amlodipine, Rosuvastatin)
The purpose of this study is to evaluate the drug-drug interaction of CKD-346(Telmisartan/S-Amlodipine, Rosuvastatin)
- Trial name
- NCT02047175
- Testing
- Telmisartan/S-Amlodipine, Rosuvastatin, Telmisartan/S-Amlodipine + Rosuvastatin
- Where
- South Korea
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Osteoporosis, Postmenopausal
A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab
The purpose of this study is to determine if denosumab is effective in increasing bone mineral density at the lumbar spine in Indian postmenopausal women with osteoporosis.
- Trial name
- NCT01495000
- Testing
- denosumab
- Where
- 11 sites in India
- Volunteers
- 250 people
- Sponsor
- GlaxoSmithKline
Amyotrophic Lateral Sclerosis
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
The primary purpose of this study is to evaluate the efficacy of ION363 on clinical function and survival in carriers of fused in sarcoma mutations with amyotrophic lateral sclerosis (FUS-ALS).
- Trial name
- NCT04768972
- Testing
- ION363
- Where
- 25 sites in United States, Belgium and 14 more
- Volunteers
- 89 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Diabetic Cardiomyopathies
Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy
This is a multicenter, randomized, placebo-controlled, 2-part study to evaluate the safety and efficacy of AT-001 in adult patients (N=675) with Diabetic Cardiomyopathy at high risk of progression to overt heart failure.
- Trial name
- NCT04083339
- Testing
- AT-001
- Where
- 79 sites in United States, Australia and 8 more
- Volunteers
- 675 people
- Sponsor
- Applied Therapeutics, Inc.
Amyotrophic Lateral Sclerosis
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
This study assessed the effect of tirasemtiv versus placebo on respiratory function in patients with ALS.
- Trial name
- VITALITY-ALS (NCT02496767)
- Testing
- Tirasemtiv
- Where
- 81 sites in United States, Belgium and 9 more
- Volunteers
- 744 people
- Sponsor
- Cytokinetics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.